Current Drug Targets

Francis J. Castellino
Kleiderer-Pezold Professor of Biochemistry
Director, W.M. Keck Center for Transgene Research
Dean Emeritus, College of Science
230 Raclin-Carmichael Hall, University of Notre Dame
Notre Dame, IN 46556


Translate in Chinese

Therapeutic Drugs in Bone Loss-Associated Disorders: Clinical Outcomes and Challenges

Author(s): Daniela M. Sousa, Ines S. Alencastre, Luís Leitao, Estrela Neto, Cecilia J. Alves, Meriem Lamghari.

Graphical Abstract:


Current therapeutic drugs for the treatment of bone loss-associated disorders such as osteoporosis and metastatic bone disease have limited clinical outcomes, namely in terms of efficiency and sustainability. Given the ageing of population in developed countries and the cumulative costs with treatment, bone loss-associated disorders represent a major socioeconomic burden worldwide. In this review, the therapeutic agents targeting bone loss tested in clinical and pre-clinical trials are summarized, as well as the challenges encountered by clinicians and patients. In an effort to attain costeffective clinical outcomes, potential cellular and signalling targets are disclosed.

Keywords: Bone loss, therapy, anabolic agents, anti-resorptive agents, clinical trials, osteoclasts, osteoblasts.

Order Reprints Order Eprints Rights & PermissionsPrintExport

Article Details

Year: 2017
Page: [696 - 704]
Pages: 9
DOI: 10.2174/1389450117666160709024547
Price: $58